"10.1371_journal.pone.0114947","plos one","2015-02-24T00:00:00Z","Yen T Duong; Reshma Kassanjee; Alex Welte; Meade Morgan; Anindya De; Trudy Dobbs; Erin Rottinghaus; John Nkengasong; Marcel E Curlin; Chonticha Kittinunvorakoon; Boonyos Raengsakulrach; Michael Martin; Kachit Choopanya; Suphak Vanichseni; Yan Jiang; Maofeng Qiu; Haiying Yu; Yan Hao; Neha Shah; Linh-Vi Le; Andrea A Kim; Tuan Anh Nguyen; William Ampofo; Bharat S Parekh","International Laboratory Branch, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; Epidemiology and Strategic Information Branch, Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America; The South African DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), University of Stellenbosch, Stellenbosch, South Africa; School of Computational and Applied Mathematics, University of the Witwatersrand, Johannesburg, South Africa; Thailand Ministry of Public Health-US CDC Collaboration, Bangkok, Thailand; National AIDS Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; California Department of Public Health, Richmond, California, United States of America; Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Hanoi, Vietnam; CDC-Kenya, Nairobi, Kenya; National Institute of Hygiene and Epidemiology, Hanoi, Vietnam; Noguchi Memorial Institute for Medical Research, Accra, Ghana","Conceived and designed the experiments: BSP YD AAK NS YJ MQ. Performed the experiments: YD TD ER MQ HY YH. Analyzed the data: BSP YD RK AW M. Morgan AD YJ MQ NS. Contributed reagents/materials/analysis tools: BSP YD RK AW M. Morgan AD MEC CK BR M. Martin KC SV YJ MQ HY YH NS LL AAK TAN WA. Wrote the paper: BSP YD RK AW JN M. Morgan AD.","BSP is an inventor of LAg-Avidity EIA and receives royalties as part of U.S. government licensing agreement with commercial partners. Recombinant protein (rIDRm) and knowhow to develop the LAg-Avidity EIA and related incidence assays have been licensed to multiple commercial partners as per open licensing policy of the U.S. Government. These commercial partners currently include 1) Sedia BioSciences, Portland, OR, 2) Maxim Biotech, Rockville, MD, and 3) Beijing KingHawk Pharmaceuticals Inc., Beijing, China. This does not alter the authors' adherence to PLOS ONE Editorial policies and criteria or adherence of PLOS ONE policies on sharing data and materials.","2015","02","Yen T Duong","YTD",24,TRUE,6,6,5,6,TRUE,TRUE,TRUE,8,"5;10;11;13;14;20;22;23",TRUE
